Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

re 13 deaths: six in the placebo group, three in the low-dose group, three in the mid-dose group and one in the high-dose group. Finally, persistence of the vector DNA as assessed by qPCR testing was demonstrated in three high dose MYDICAR patients in whom a biopsy was feasible, but not from patients in the placebo or lower dose groups.  No safety concerns were noted during the three year follow-up period.

About the CUPID 1 Trial
Phase 2a of the CUPID 1 trial was a clinical trial using Celladon's lead product candidate MYDICAR in patients with advanced heart failure. In this 39-patient trial, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms and quality of life, and improved key markers of cardiac function predictive of survival, such as elevated levels of natriuretic peptides and end systolic volume.  Three dose levels of MYDICAR were administered, and the high-dose MYDICAR group met the primary endpoint versus placebo at six months, and all positive trends were confirmed at 12 months. The hazard ratio at 12 months for the high-dose MYDICAR group versus placebo for recurrent adjudicated clinical events was 0.12 (p=0.003) representing a risk reduction of 88% with MYDICAR versus placebo. No safety concerns were noted.

About Celladon
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme defic
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... Ocean energy company, BioPower Systems (BPS), today announced ... Hon. Michael O,Brien MP, has awarded the company conditional ... Pilot Demonstration Program. The funding will be ... company,s 250kW bioWAVE ocean wave energy system at a ...
... RSB Spine announced today that it received a revised ... an interbody implant with integrated fixation and an anterior ... for stand-alone interbody devices with integrated fixation.   The new ... new code for cervical interbody devices is OVE.   In ...
... 30, 2011  Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology ... Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced ... publishing a mechanism study on the use of Alpha-Cobratoxin, ... pain. The paper was co-authored by Paul Reid, PhD ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 3
(Date:9/12/2014)... an active role in the destruction and remodelling ... being an ,innocent bystander, as previously thought. , ... Lawler, Dr Ben Croker and colleagues from the ... while investigating the role of the protein SOCS3 ... was published in the journal Arthritis and ...
(Date:9/12/2014)... coccidiosis is a serious parasitic infection of young ... to diarrhoea and reduced nutritional intake. As the ... can result in increased mortality, the disease is ... farms., "The developing immune system of neonatal piglets ... the parasites. For this reason, an infection shortly ...
(Date:9/11/2014)... with autism often show a reduced frequency of ... in repetitive solitary behaviors. Autism has also been ... structure involved in processing emotions. Now Caltech researchers ... amygdala that control whether the animal engages in ... may have implications for understanding neural circuit dysfunctions ...
Breaking Biology News(10 mins):No innocent bystander: Cartilage contributes to arthritis 2Piglet health 2Piglet health 3Tipping the balance of behavior 2Tipping the balance of behavior 3
... the late 1800s, a flurry of fossil speculation across the ... Bone Wars. Drawn into the spectacle were two scientists ... acclaimed as the Father of Texas Geology, and naturalist Jacob ... Hill and Boll had supporting roles in the Bone ...
... to the amount of unhealthy foods they eat, but can ... new study in the Journal of Consumer Research . ... willpower and desire, consumers can,t rely entirely on willpower to ... will make them lose interest in food. One way is ...
... side-effects caused by the anti-parasitic drug quinine in the treatment ... The research, carried out by Nottingham scientists on the University,s ... in our levels of the amino acid, tryptophan, has a ... appears that the lower our levels of tryptophan the more ...
Cached Biology News:Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 2Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 3Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 4Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 5Eat dessert first? It might help you control your diet 2Diet could combat adverse side-effects of quinine 2Diet could combat adverse side-effects of quinine 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: